Turning Point and Zai Lab Broaden Collaboration
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning Point’s MET/SRC/CSF1R Inhibitor, in Greater China Turning Point to
Read moreUS90041T1088
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Updated Data from TRIDENT-1 Study in TKI-Naive Patients with ROS1-Positive Non-Small Cell Lung Cancer Planned for Presentation at Upcoming World
Read moreTurning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference
SAN DIEGO, Nov. 10, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation
Read moreTurning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation
Read moreTurning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock
SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation
Read moreTurning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium
Preliminary Clinical Activity and Safety Profile Support Advancing to Dose Expansion in Multiple Tumor Types Recommended Phase 2 Dose Determination
Read moreTurning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) —
Read moreTurning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium
Discussion to Include Initial Phase 1 Data from Ongoing SHIELD-1Trial of TPX-0022 SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) —
Read moreTurning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation
Read moreTurning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium
Two Additional Abstracts Selected for Poster Presentations of Preclinical Data for Lead Drug Candidate Repotrectinib SAN DIEGO, Oct. 07, 2020
Read more